Polysaccharide microparticles containing biological agents: their preparation and applications
    1.
    发明授权
    Polysaccharide microparticles containing biological agents: their preparation and applications 有权
    含有生物制剂的多糖微粒:其制备及应用

    公开(公告)号:US08932633B2

    公开(公告)日:2015-01-13

    申请号:US12065310

    申请日:2006-07-20

    摘要: A method of preparing polysaccharide glassy microparticles which are less than 10 μum in diameter and contain structurally delicate agents, such as proteins, peptides, gene materials, vaccines, antibodies, viruses and liposomes using low-temperature aqueous-aqueous emulsification (free of polyelectrolytes) and freezing-induced phase separation. When delicate agents are added to a polysaccharide-PEG two phase system followed by homogenization (or other shear adding process), the agents partition into the polysaccharide dispersed phase preferentially. These processes help to avoid aggregation of proteins caused by interaction with charged polyelectrolytes used for stabilizing the polysaccharide dispersed phase in our previously reported aqueous-aqueous emulsion. When this system is frozen and lyophilized, glassy particles less than 10 μm in diameter containing delicate agents can be formed. These fine polysaccharide particles protect proteins within their hydrophilic glassy matrix, and can therefore be easily suspended in hydrophobic polymer solutions and formulated to various forms of sustained release devices such microsphere, sheets, fibers, coating layers, and scaffolds. The particles can also be dispersed in hydrophilic gels to improve releasing kinetics and to deliver vaccines and antibodies for immune therapy.

    摘要翻译: 使用低温水性乳化(无聚电解质)制备直径小于10μm的多糖玻璃状微粒的方法,其含有结构上脆弱的物质,例如蛋白质,肽,基因材料,疫苗,抗体,病毒和脂质体, 和冷冻诱导相分离。 当将精制剂加入到多糖-PEG两相体系中,随后进行均质化(或其他剪切加料法)时,试剂优先分配到多糖分散相中。 这些过程有助于避免与我们以前报道的水性乳液中稳定多糖分散相的带电聚电解质相互作用引起的蛋白质聚集。 当该系统被冷冻和冻干时,可以形成直径小于10μm的含有细腻剂的玻璃状颗粒。 这些细多糖颗粒保护其亲水玻璃质基质内的蛋白质,因此可以容易地悬浮在疏水性聚合物溶液中并配制成各种形式的缓释装置如微球,片,纤维,涂层和支架。 颗粒也可以分散在亲水性凝胶中,以改善释放动力学和递送用于免疫治疗的疫苗和抗体。

    Polysaccharide Microparticles Containing Biological Agents: Their Preparation and Applications
    2.
    发明申请
    Polysaccharide Microparticles Containing Biological Agents: Their Preparation and Applications 有权
    含有生物制剂的多糖微粒:的制备与应用

    公开(公告)号:US20080248098A1

    公开(公告)日:2008-10-09

    申请号:US12065310

    申请日:2006-07-20

    摘要: A method of preparing polysaccharide glassy microparticles which are less than 10 μum in diameter and contain structurally delicate agents, such as proteins, peptides, gene materials, vaccines, antibodies, viruses and liposomes using low-temperature aqueous-aqueous emulsification (free of polyelectrolytes) and freezing-induced phase separation. When delicate agents are added to a polysaccharide-PEG two phase system followed by homogenization (or other shear adding process), the agents partition into the polysaccharide dispersed phase preferentially. These processes help to avoid aggregation of proteins caused by interaction with charged polyelectrolytes used for stabilizing the polysaccharide dispersed phase in our previously reported aqueous-aqueous emulsion. When this system is frozen and lyophilized, glassy particles less than 10 μm in diameter containing delicate agents can be formed. These fine polysaccharide particles protect proteins within their hydrophilic glassy matrix, and can therefore be easily suspended in hydrophobic polymer solutions and formulated to various forms of sustained release devices such microsphere, sheets, fibers, coating layers, and scaffolds. The particles can also be dispersed in hydrophilic gels to improve releasing kinetics and to deliver vaccines and antibodies for immune therapy.

    摘要翻译: 一种制备多糖玻璃状微粒的方法,其使用低温水性乳化(不含聚电解质),其直径小于10um,并含有结构上脆弱的物质,例如蛋白质,肽,基因材料,疫苗,抗体,病毒和脂质体。 和冷冻诱导相分离。 当将精制剂加入到多糖-PEG两相体系中,随后进行均质化(或其他剪切加料法)时,试剂优先分配到多糖分散相中。 这些过程有助于避免与我们以前报道的水性乳液中稳定多糖分散相的带电聚电解质相互作用引起的蛋白质聚集。 当该系统被冷冻和冻干时,可以形成含有微细剂的直径小于10微米的玻璃状颗粒。 这些细多糖颗粒保护其亲水性玻璃质基质内的蛋白质,因此可以容易地悬浮在疏水性聚合物溶液中并配制成各种形式的缓释装置如微球,片,纤维,涂层和支架。 颗粒也可以分散在亲水性凝胶中,以改善释放动力学和递送用于免疫治疗的疫苗和抗体。

    Process for preparation of stable fatty alcohol emulsion
    3.
    发明授权
    Process for preparation of stable fatty alcohol emulsion 有权
    稳定脂肪醇乳液的制备方法

    公开(公告)号:US09321907B2

    公开(公告)日:2016-04-26

    申请号:US13990768

    申请日:2012-06-04

    摘要: Described is a method for preparation of stable fatty alcohol emulsion, wherein, fatty acid esters are introduced into an antifoaming agent emulsion system, and an anionic surfactant is added in the late stage of emulsification process in order to further improve the stability of the emulsion. The anionic surfactant is absorbed to the surface of fatty alcohol particles to make the fatty alcohol emulsion more stable under the action of ionic mutual repulsion. The prepared fatty alcohol emulsion has favorable foam elimination and suppression performance in the paper making procedure, and is stable during storage.

    摘要翻译: 描述了稳定的脂肪醇乳液的制备方法,其中将脂肪酸酯引入消泡剂乳液体系中,并且在乳化过程的后期加入阴离子表面活性剂以进一步提高乳液的稳定性。 阴离子表面活性剂被吸收到脂肪醇颗粒的表面,使得脂肪醇乳液在离子相互斥力的作用下更加稳定。 制备的脂肪醇乳液在造纸过程中具有良好的泡沫消除和抑制性能,并且在储存期间是稳定的。

    NEW-TYPE PAPERMAKING WET-END DEFOAMER
    4.
    发明申请
    NEW-TYPE PAPERMAKING WET-END DEFOAMER 审中-公开
    新型造纸水洗脱水机

    公开(公告)号:US20110213053A1

    公开(公告)日:2011-09-01

    申请号:US13057267

    申请日:2010-09-01

    IPC分类号: C08L63/00

    摘要: A new-type papermaking wet-end defoamer and methods of making relating to the field of the chemical preparations for use in papermaking. The defoamer including 5˜99% FAME (fatty acid methyl ester) derivatives having a general structural formula of R1CO(EO)x(PO)yOCH3, molecular weight of 300˜3000 and a turbidity point of 20˜80° C.; which are the products of the addition reaction of FAME as an initiator and EO (ethylene oxide) and/or PO (propylene oxide) under the action of catalyst. The defoamer also including 0.1˜80% polyether having a general structural formula of R2{M(EO)m(PO)nH}a, a molecular weight of 500˜8000 and a turbidity point of 10˜80° C. The defoamer also including a 0.1˜70% modified polyether, with a general structural formula of R2{M(EO)m(PO)nR3}a. The defoamer also including 0.1˜20% natural oil and fat. The new-type papermaking wet-end defoamer is not only applicable to the papermaking wet-end process but also applicable to papermaking wastewater treatment and the elimination of other aqueous foam.

    摘要翻译: 一种新型造纸湿式消泡剂,以及与造纸中使用的化学制剂领域相关的制备方法。 消泡剂包括具有通式结构式为R 1 CO(EO)x(PO)y OCH 3,分子量为300〜3000,浊度为20〜80℃的5〜99%FAME(脂肪酸甲酯)衍生物。 它们是在催化剂作用下作为引发剂和EO(环氧乙烷)和/或PO(环氧丙烷)的加成反应的产物。 消泡剂还包括具有通式结构式为R 2(M(EO)m(PO)n H} a的0.1〜80%的聚醚,分子量为500〜8000,浊点为10〜80℃。消泡剂也 包括具有通式结构式为R 2 {M(EO)m(PO)n R 3} a的0.1〜70%的改性聚醚。 消泡剂中还含有0.1〜20%天然油脂。 新型造纸湿式消泡剂不仅适用于造纸湿端工艺,而且适用于造纸废水处理和其他水性泡沫的消除。

    Method and kit for discriminating between breast cancer and benign breast disease
    6.
    发明授权
    Method and kit for discriminating between breast cancer and benign breast disease 有权
    用于区分乳腺癌和良性乳腺疾病的方法和试剂盒

    公开(公告)号:US09410188B2

    公开(公告)日:2016-08-09

    申请号:US13696937

    申请日:2010-05-28

    IPC分类号: C12Q1/68

    摘要: A method and kit are related to discriminating between breast cancer and benign breast disease by the determination of the expression level of at least one target gene including a nucleic acid sequence selected from the nucleic acid sequences set forth in SEQ ID NOs: 1, 2 or 3, 4 and 5 or 6 to obtain an expression profile for the patient, and the comparison of the expression profile of the patient with expression profiles of target genes from patients previously clinically classified as breast cancer and expression profiles of target genes from patients previously clinically classified as benign breast disease.

    摘要翻译: 一种方法和试剂盒涉及通过测定至少一种靶基因的表达水平来区分乳腺癌和良性乳腺疾病,所述至少一种靶基因包括选自SEQ ID NO:1,2所示的核酸序列的核酸序列,或 3,4和5或6以获得患者的表达谱,并且将患者的表达谱与先前临床分类为乳腺癌的患者的靶基因的表达谱和先前临床患者的靶基因的表达谱进行比较 归为良性乳腺疾病。

    METHOD AND KIT FOR DETERMINING IN VITRO THE PROBABILITY FOR AN INDIVIDUAL TO SUFFER FROM COLORECTAL CANCER
    7.
    发明申请
    METHOD AND KIT FOR DETERMINING IN VITRO THE PROBABILITY FOR AN INDIVIDUAL TO SUFFER FROM COLORECTAL CANCER 有权
    用于确定个体对彩色癌症的可能性的方法和工具

    公开(公告)号:US20140057802A1

    公开(公告)日:2014-02-27

    申请号:US14007439

    申请日:2012-03-23

    IPC分类号: C12Q1/68

    CPC分类号: C12Q1/6886 C12Q2600/158

    摘要: The present invention provides a method for determining in vitro, in a peripheral blood sample, the probability for an individual to suffer from a colorectal cancer, using the comparison of the amount of expression products of nucleic acids of genes of the individual to be tested with the amount of expression products of nucleic acids of the same genes obtained from a CRC group of patients constituting the positive control and with the amount of expression products of nucleic acids of the same genes obtained from a CNC group of individuals constituting the negative control; and a kit comprising specific binding partners for said expression products.

    摘要翻译: 本发明提供了一种用于在外周血样品中测定个体遭受结肠直肠癌的可能性的方法,该方法使用待测个体的基因的核酸的表达产物的量与 从构成阳性对照的CRC组获得的相同基因的核酸的表达产物的量以及从构成阴性对照的个体的CNC组获得的相同基因的核酸的表达产物的量; 以及包含所述表达产物的特异性结合伴侣的试剂盒。

    METHOD AND KIT FOR DISCRIMINATING BETWEEN BREAST CANCER AND BENIGN BREAST DISEASE
    8.
    发明申请
    METHOD AND KIT FOR DISCRIMINATING BETWEEN BREAST CANCER AND BENIGN BREAST DISEASE 有权
    用于鉴别乳腺癌和勃起乳腺疾病之间的方法和工具包

    公开(公告)号:US20130072399A1

    公开(公告)日:2013-03-21

    申请号:US13696937

    申请日:2010-05-28

    IPC分类号: C12Q1/68

    摘要: A method and kit are related to discriminating between breast cancer and benign breast disease by the determination of the expression level of at least one target gene including a nucleic acid sequence selected from the nucleic acid sequences set forth in SEQ ID NOs: 1, 2 or 3, 4 and 5 or 6 to obtain an expression profile for the patient, and the comparison of the expression profile of the patient with expression profiles of target genes from patients previously clinically classified as breast cancer and expression profiles of target genes from patients previously clinically classified as benign breast disease.

    摘要翻译: 一种方法和试剂盒涉及通过测定至少一种靶基因的表达水平来区分乳腺癌和良性乳腺疾病,所述至少一种靶基因包括选自SEQ ID NO:1,2所示的核酸序列的核酸序列,或 3,4和5或6以获得患者的表达谱,并且将患者的表达谱与先前临床分类为乳腺癌的患者的靶基因的表达谱和先前临床患者的靶基因的表达谱进行比较 归为良性乳腺疾病。

    Image sensor having waveguides formed in color filters
    9.
    发明授权
    Image sensor having waveguides formed in color filters 有权
    具有形成在滤色器中的波导的图像传感器

    公开(公告)号:US08269264B2

    公开(公告)日:2012-09-18

    申请号:US12615048

    申请日:2009-11-09

    IPC分类号: H01L31/062

    摘要: An image sensor having an array of pixels disposed in a substrate. Each pixel includes a photosensitive element, a color filter, and waveguide walls. The waveguide walls are disposed in the color filter and surround portions of the color filter to form waveguides through the color filter. The refractive index of the waveguide walls is less than the refractive index of the color filter. The image sensor may be back side illuminated (BSI) or front side illuminated (FSI). In some embodiments, metal walls may be coupled to the waveguide walls.

    摘要翻译: 一种具有设置在基板中的像素阵列的图像传感器。 每个像素包括感光元件,滤色器和波导壁。 波导壁设置在滤色器中并且围绕滤色器的部分以形成通过滤色器的波导。 波导壁的折射率小于滤色器的折射率。 图像传感器可以是背面照明(BSI)或前侧照明(FSI)。 在一些实施例中,金属壁可以耦合到波导壁。

    VISIBLE AND INFRARED DUAL MODE IMAGING SYSTEM
    10.
    发明申请
    VISIBLE AND INFRARED DUAL MODE IMAGING SYSTEM 有权
    可见和红外双模式成像系统

    公开(公告)号:US20120087645A1

    公开(公告)日:2012-04-12

    申请号:US12902901

    申请日:2010-10-12

    IPC分类号: G03B17/00 H04N5/225

    CPC分类号: H04N5/33 H04N5/332 H04N9/04

    摘要: An imaging system includes an image sensor and an optical filter. The image sensor captures image data in response to incident light. The optical filter filters the light and includes a dual window transmission spectrum. The dual window transmission spectrum includes a first transmission window having a first pass band aligned to pass visible light and a second transmission window having a second pass band overlapping with an absorption band of infrared light in Earth's atmosphere.

    摘要翻译: 成像系统包括图像传感器和滤光器。 图像传感器根据入射光捕获图像数据。 光滤波器对光进行滤光并包括双窗透射光谱。 双窗透射光谱包括具有对准以通过可见光的第一通带的第一透射窗和具有与地球大气中的红外光的吸收带重叠的第二通带的第二透射窗。